Contents

Preface xvii
Acknowledgments xix

Part One Introduction to Fundamental Medical Mycology, Laboratory Diagnostic Methods, and Antifungal Therapy

1. Introduction to Fundamental Medical Mycology 3
   1.1 Topics not Covered, or Receiving Secondary Emphasis 3
   1.2 Biosafety Considerations: Before You Begin Work with Pathogenic Fungi... 3
      1.2.1 Biological Safety Cabinets (BSC) 4
      1.2.2 Precautions to Take in Handling Etiologic Agents that Cause Systemic Mycoses 4
      1.2.3 Additional Precautions at Biosafety Level 3 (BSL 3) 5
      1.2.4 Safety Training 5
      1.2.5 Disinfectants and Waste Disposal 5
   1.3 Fungi Defined: Their Ecologic Niche 5
   1.4 Medical Mycology 5
   1.5 A Brief History of Medical Mycology 6
      1.5.1 Ancient Greece 6
      1.5.2 Middle Ages 6
      1.5.3 Twentieth Century 6
      1.5.4 Endemic Mycoses in the Americas 6
      1.5.5 Era of Immunosuppression in the Treatment of Cancer, Maintenance of Organ Transplants, and Autoimmune Diseases 7
      1.5.6 Opportunistic Mycoses 7
      1.5.7 HIV/AIDS 7
      1.5.8 Twenty-first Century 8
   1.6 Rationale for Fungal Identification 9
      1.6.1 Developing the Treatment Plan 9
   1.6.2 Investigating Outbreaks 10
   1.6.3 Determining the Susceptibility to Antifungal Agents 10
   1.6.4 Estimating the Significance of Fungi Generally Considered to be Opportunists or Saprobes 10
   1.6.5 Types of Vegetative Growth 10
   1.7 Sporulation 11
   1.8 Dimorphism 11
      1.8.1 Dimorphism and Pathogenesis 12
   1.9 Sex in Fungi 13
      1.9.1 Anamorph and Teleomorph Nomenclature 13
   1.10 Classification of Mycoses Based on the Primary Site of Pathology 13
      1.10.1 Superficial Mycoses 13
      1.10.2 Cutaneous Mycoses 13
      1.10.3 Systemic Opportunistic Mycoses 13
      1.10.4 Subcutaneous Mycoses 13
      1.10.5 Endemic Mycoses Caused by Dimorphic Environmental Molds 13
   1.11 Taxonomy/Classification: Kingdom Fungi 14
      1.11.1 The Phylogenetic Species Concept for Classification 15
      1.11.2 The Higher Level Classification of Kingdom Fungi 15
   1.12 General Composition of the Fungal Cell 21
      1.12.1 Yeast Cell Cycle 21
      1.12.2 Hyphal Morphogenesis 21
      1.12.3 Cell Wall 22
   1.13 Primary Pathogens 25
      1.13.1 Susceptibility to Primary Pathogens 26
   1.14 Endemic Versus Worldwide Presence 26
   1.15 Opportunistic Fungal Pathogens 26
      1.15.1 Susceptibility to Opportunistic Fungal Pathogens: Host Factors 26
   1.16 Determinants of Pathogenicity 27
3A.6.1 Action Spectrum 91
3A.6.2 Pharmacokinetics 91
3A.6.3 Drug Interactions 92
3A.6.4 Adverse Reactions 92
3A.7 Azole Resistance Mechanisms 92
3A.7.1 Alteration of Target Enzyme 
(Lanosterol Demethylase) 92
3A.7.2 Overexpression of Target 
Enzyme 92
3A.7.3 Increased Efflux of Drug, CDR Efflux 
Pumps 92
3A.7.4 Bypass Pathways 92
3A.7.5 Loss of Heterozygosity in 
Chromosome 5 and Azole 
Resistance 92
3A.7.6 Azole Resistance in Aspergillus 
Species 93
3A.8 Echinocandins 93
3A.8.1 Mode of Action 93
3A.8.2 Spectrum of Activity 93
3A.9 Caspofungin (CASF) (Cancidas 
®, Merck) 94
3A.9.1 Action Spectrum 94
3A.9.2 Dosage 95
3A.9.3 Pharmacokinetics 95
3A.9.4 Drug Interactions 95
3A.9.5 Adverse Reactions 95
3A.10 Micafungin (MCF) (Mycaminet 
®, Astellas 
Pharma, Inc.) 95
3A.10.1 Indications 95
3A.10.2 Dosage 95
3A.10.3 Metabolism 96
3A.10.4 Drug Interactions 96
3A.10.5 Adverse Reactions 97
3A.11 Anidulafungin (ANF) (Eraxis 
®, Pfizer) 96
3A.11.1 Indications 96
3A.11.2 Invasive Candidiasis 96
3A.11.3 Molds 96
3A.11.4 Dosage 96
3A.11.5 Metabolism 96
3A.11.6 Drug Interactions 97
3A.11.7 Adverse Reactions 97
3A.12 Terbinafine (TRB) (Lamisil 
®, Novartis) 97
3A.12.1 Mode of Action 97
3A.12.2 Action Spectrum 97
3A.12.3 Drug Synergy 97
3A.12.4 Metabolism 97
3A.12.5 Adverse Reactions 98
3A.13 5-Fluorocytosine (Flucytosine, 5FC) 
(Ancobon®, Valeant 
Pharmaceuticals) 98
3A.13.1 Indications 98
3A.13.2 Combination Therapy 98
3A.13.3 Metabolism 98
3A.13.4 Adverse Reactions 98
3A.14 Griseofulvin (Grifulvin V, Ortho 
Pharmaceutical Corp.) 99
3A.14.1 Mode of Action 99
3A.14.2 Action Spectrum 99
3A.14.3 Indications 99
3A.14.4 Dosage Regimen 99
3A.14.5 Metabolism 99
3A.14.6 Adverse Reactions 100
3A.15 Combination Therapy 100
3A.16 Suppressive or Maintenance 
Therapy 100
3A.17 Prophylactic Therapy 100
3A.17.1 Bimodal Period of Risk 101
3A.17.2 Fluconazole and Alternatives for 
Primary Prophylaxis 101
3A.17.3 Prophylaxis in Patients During the 
Pre-engraftment Period with a History 
of Invasive Mold Infections 102
3A.17.4 Prophylaxis in the Post-engraftment 
Period 102
3A.18 Empiric Therapy 102
3A.19 Innately Resistant Fungi 103
3A.19.1 Innately Resistant Molds 103
3A.19.2 Innately Resistant Yeasts 103
3A.20 General Reference for Antifungal Agents 
and Therapy 103
3A.21 Selected References for Antifungal Agents 
and Therapy 103
3A.22 Websites Cited 105
3A.23 Questions 105
3B. Antifungal Susceptibility Tests 107
3B.1 Antifungal Susceptibility Tests 
Defined 107
3B.2 National and International Standards for 
AFS Tests 107
3B.3 Objective of AFS Tests 107
3B.4 Minimum Inhibitory Concentration (MIC) 
of an Antifungal Drug Defined 107
3B.4.1 MIC₅₀ and MIC₉₀ 108
3B.5 Broth Microdilution (BMD) 
Method 108
3B.6 Clinical Indications for AFS 
Testing 108
3B.7 Correlation Between the In Vitro 
determined MIC and the Clinical Efficacy 
of Drug Therapy 108
3B.7.1 How Are the Conditions of 
“Susceptible” or “Resistant” 
Determined? 109
3B.7.2 What Are Breakpoints? 109
3B.7.3 Minimum Effective 
Concentration 109
3B.8 AFS Methods Currently Available for Use 
in the Clinical Laboratory 110
3B.8.1 Broth Microdilution (BMD) 
Method 110
3B.8.2 Etest® 110
3B.8.3 Disk Diffusion Method 110
3B.9 Which Laboratories Conduct AFS Tests? 110
3B.10 Principles of AFS Tests 110
3B.10.1 Standard Method for AFS Testing of Yeasts 110
3B.10.2 Modifications Suggested to Improve Performance of the BMD Method for Yeast 112
3B.10.3 Commercial BMD Method with Precoated Drug Panels: A CLSI-Approved Method for AFS Testing of Yeasts and Molds 113
3B.10.4 Standardization of AFS Tests for Molds, M38-A2: BMD Method for Yeasts 114
3B.10.5 Etest® (bioMérieux, Marcy l’Etoile, France) 114
3B.10.6 Disk Diffusion AFS Tests 117
3B.10.7 VITEK 2® System for AFS (bioMérieux, Marcy l’Etoile, France) 118
3B.10.8 Flow Cytometry AFS Test 118
3B.11 Summary of the Current Status of Antifungal Susceptibility Testing 119

Questions 121

5. Coccidioidomycosis 141
5.1 Coccidioidomycosis-at-a-Glance 141
5.2 Introduction/Disease Definition 141
5.3 Case Presentations 142
5.4 Diagnosis 143
5.5 Etiologic Agents 143
5.6 Geographic Distribution/Ecologic Niche 144
5.7 Epidemiology 147
5.7.1 Incidence and Prevalence 147
5.7.2 Effect of Weather on Annual Fluctuations in Prevalence of Coccidioidomycosis 148
5.8 Risk Groups/Factors 149
5.9 Transmission 150
5.10 Determinants of Pathogenicity and Pathogenesis 151
5.10.1 Allergic Findings 151
5.10.2 Pathology 151
5.10.3 Host Factors 151
5.10.4 Pathogenesis 153
5.10.5 Vaccine Development 154
5.10.6 Attenuated Live Chitinase Mutant C. posadasii 154
5.11 Clinical Forms 155
5.12 Veterinary Forms 156
5.13 Therapy 156
5.14 Laboratory Detection, Recovery, and Identification 158
Selected References for Coccidioidomycosis 162
Websites Cited 163
Questions 164

6. Histoplasmosis 165
6.1 Histoplasmosis-at-a-Glance 165
6.2 Introduction/Disease Definition 165
6.3 Case Presentations 166
6.4 Etiologic Agents 169
6.5 Geographic Distribution/Ecologic Niche 170
6.6 Epidemiology 171
6.6.1 Incidence and Prevalence 171
6.6.2 Risk Groups/Factors 171
6.7 Transmission 171
6.8 Determinants of Pathogenicity 172
6.8.1 Host Factors 172
6.8.2 Microbial Factors 173
6.9 Clinical Forms 175

Part Two Systemic Mycoses Caused by Dimorphic Environmental Molds (Endemic Mycoses) 125

4. Blastomycosis 125
4.1 Blastomycosis-at-a-Glance 125
4.2 Introduction/Disease Definition 125
4.3 Case Presentations 126
4.4 Diagnosis 127
4.5 Etiologic Agent 127
4.6 Geographic Distribution/Ecologic Niche 128
4.7 Epidemiology 129
4.8 Risk Groups/Factors 129
4.9 Transmission 129
4.10 Determinants of Pathogenicity 130
4.10.1 Pathogenesis 130
4.10.2 Host Factors 130
4.10.3 Microbial Factors 130
4.11 Clinical Forms 131
4.12 Veterinary Forms 133
4.13 Therapy 133
4.14 Laboratory Detection, Recovery, and Identification 134
General Reference for Blastomycosis 137

Questions 138

Selected References for Blastomycosis 137

Websites Cited 163
Questions 164
# 1. Histoplasmosis

## 6. Laboratory Detection, Recovery, and Identification

- **6.10 Veterinary Forms**
- **6.11 Therapy**
- **6.12 Laboratory Detection, Recovery, and Identification**

**Selected References for Histoplasmosis**

**Websites Cited**

**Questions**

# 2. Paracoccidioidomycosis

## 7. Paracoccidioidomycosis

- **7.1 Paracoccidioidomycosis-at-a-Glance**
- **7.2 Introduction/Disease Definition**
- **7.3 Case Presentation**
- **7.4 Etiologic Agent**
- **7.5 Geographic Distribution/Ecologic Niche**
- **7.6 Epidemiology**
- **7.7 Transmission**
- **7.8 Determinants of Pathogenicity**
- **7.9 Clinical Forms**
- **7.10 Veterinary Forms**
- **7.11 Therapy**
- **7.12 Laboratory Detection, Recovery, and Identification**

**Selected References for Paracoccidioidomycosis**

**Questions**

# 3. Penicilliosis

## 8. Penicilliosis

- **8.1 Penicilliosis-at-a-Glance**
- **8.2 Introduction/Disease Definition**
- **8.3 Case Presentation**
- **8.4 Diagnosis**
- **8.5 Etiologic Agents**
- **8.6 Geographic Distribution/Ecologic Niche**
- **8.7 Epidemiology**
- **8.8 Risk Groups/Factors**
- **8.9 Transmission**
- **8.10 Determinants of Pathogenicity**
- **8.11 Clinical Forms**
- **8.12 Veterinary Forms**
- **8.13 Therapy**

**Selected References for Penicilliosis**

**Website Cited**

**Questions**

# 4. Sporotrichosis

## 9. Sporotrichosis

- **9.1 Sporotrichosis-at-a-Glance**
- **9.2 Introduction/Disease Definition**
- **9.3 Case Presentations**
- **9.4 Diagnosis**
- **9.5 Etiologic Agents**
- **9.6 Geographic Distribution/Ecologic Niche**
- **9.7 Epidemiology**
- **9.8 Transmission**
- **9.9 Determinants of Pathogenicity**
- **9.10 Clinical Forms**
- **9.11 Human–Animal Interface**
- **9.12 Therapy**
- **9.13 Laboratory Detection, Recovery, and Identification**

**Selected References for Sporotrichosis**

**Questions**

# 5. Adiaspiromycosis

## 10. Less Frequent Mycoses Caused by Dimorphic Environmental Molds:

- **10A. Adiaspiromycosis**

  - **10A.1 Adiaspiromycosis-at-a-Glance**
  - **10A.2 Introduction/Disease Definition**
  - **10A.3 Case Summaries**
  - **10A.4 Diagnosis**
  - **10A.5 Etiologic Agents**
  - **10A.6 Geographic Distribution/Ecologic Niche**
  - **10A.7 Epidemiology/Risk Groups/Factors**
  - **10A.8 Transmission**
  - **10A.9 Determinants of Pathogenicity**
  - **10A.10 Clinical Forms**
  - **10A.11 Veterinary Forms**
  - **10A.12 Therapy**
  - **10A.13 Laboratory Detection, Recovery, and Identification**

**Selected References for Adiaspiromycosis**

**Questions**
10B. Less Frequent Mycoses Caused by Dimorphic Environmental Molds (Endemic Mycoses): Lobomycosis
(Jorge Lóbo’s Disease) 241

10B.1 Lobomycosis-at-a-Glance 241
10B.2 Introduction/Disease Definition 242
10B.3 Case Presentations 242
10B.4 Diagnosis 244
10B.5 Etiologic Agent 244
10B.6 Geographic Distribution/Ecologic Niche 244
10B.7 Epidemiology 244
10B.8 Risk Groups/Factors 244
10B.9 Transmission 244
10B.10 Determinants of Pathogenicity 245
10B.10.1 Host Factors 245
10B.10.2 Microbial Factors 245
10B.11 Clinical Forms 245
10B.12 Veterinary Forms 245
10B.13 Therapy 246
10B.14 Laboratory Detection, Recovery, and Identification 246
Selected References for Lobomycosis 246
Questions 247

Part Three: Systemic Mycoses Caused by Opportunistic Yeasts and Pneumocystis

11. Candidiasis and Less Common Yeast Genera 251

11.1 Candidiasis-at-a-Glance 251
11.2 Introduction/Disease Definition 251
11.3 Case Presentations 252
11.4 Diagnosis 255
11.5 Etiologic Agents and their Ecologic Niches 255
11.5.1 Classification of Candida Species 255
11.5.2 Less Common Candida Species of Clinical Importance 257
11.6 Epidemiology 258
11.6.1 Major Types of Candidiasis 258
11.7 Risk Groups/Factors 264
11.7.1 Invasive Candidiasis 264
11.7.2 Mucosal Candidiasis 264
11.7.3 Cutaneous Candidiasis 265
11.8 Transmission 265
11.9 Clinical Forms 266
11.10 Determinants of Pathogenicity 273
11.10.1 Host Factors 273
11.10.2 Microbial Factors 276
11.11 Therapy 282
11.12 Laboratory Detection, Recovery, and Identification 286
11.13 Less Common Opportunistic Yeast Genera 292
11.13.1 Geotrichum capitatum (Blastoschizomyces capitatus) 292
11.13.2 Rhodotorula Species 294
11.13.3 Saccharomyces cerevisiae 295
Selected References for Candidiasis 297
Questions 301

12. Cryptococcosis 303

12.1 Cryptococcosis-at-a-Glance 303
12.2 Introduction/Disease Definition 303
12.3 Case Presentations 304
12.4 Etiologic Agents 307
12.5 Geographic Distribution/Ecologic Niche 311
12.6 Epidemiology 312
12.7 Risk Groups/Factors 315
12.8 Transmission 316
12.9 Determinants of Pathogenicity 316
12.9.1 Host Factors 316
12.9.2 Microbial Factors 318
12.10 Clinical Forms 321
12.11 Veterinary Forms 323
12.12 Therapy 324
12.13 Laboratory Detection, Recovery, and Identification 326
General References for Cryptococcosis 329
Selected References for Cryptococcosis 329
Websites of Interest or Cited 331
Questions 331

13. Pneumocystosis 333

13.1 Pneumocystosis-at-a-Glance 333
13.2 Introduction/Disease Definition 333
13.3 Case Presentation 334
13.4 Etiologic Agent 335
13.5 Geographic Distribution/Ecologic Niche 336
13.6 Epidemiology 337
13.7 Risk Groups/Factors 339
13.8 Transmission 340
13.9 Determinants of Pathogenicity 340
13.9.1 Host Factors 340
13.9.2 Microbial Factors 342
13.10 Clinical Forms 343
13.11 Therapy 346
13.12 Laboratory Detection, Recovery, and Identification 348
Selected References for Pneumocystosis 351 Questions 352

Part Four Systemic Mycoses Caused by Opportunistic Hyaline Molds

14. Aspergillosis 357
14.1 Aspergillosis-at-a-Glance 357
14.2 Introduction/Disease Definition 358
14.3 Case Presentations 358
14.3.1 Diagnosis 360
14.4 Etiologic Agents 361
14.5 Geographic Distribution/Ecologic Niche 362
14.6 Epidemiology and Risk Groups/Factors 363
14.7 Transmission 369
14.8 Determinants of Pathogenicity 370
14.8.1 Host Factors 370
14.8.2 Microbial Factors 372
14.9 Clinical Forms 375
14.10 Veterinary Forms 378
14.11 Therapy 379
14.12 Laboratory Detection, Recovery, and Identification 383
Selected References for Aspergillosis 390
Websites Cited 393 Questions 393
Appendix 395

15. Fusarium Mycosis 397
15.1 Fusarium Mycosis-at-a-Glance 397
15.2 Introduction/Disease Definition 398
15.3 Case Presentation 398
15.3.1 Diagnosis 399
15.4 Etiologic Agents 399
15.5 Geographic Distribution/Ecologic Niche 399
15.6 Epidemiology 399
15.6.1 Incidence and Prevalence 399
15.6.2 Risk Factors 400

15.7 Transmission 401
15.8 Determinants of Pathogenicity 401
15.8.1 Host Factors 401
15.8.2 Microbial Factors 401
15.9 Clinical Forms 402
15.10 Veterinary Forms 404
15.11 Therapy 405
15.12 Laboratory Detection, Recovery, and Identification 407
Selected References for Fusarium Mycosis 410
Website Cited 411 Questions 411

16. Pseudallescheria/Scedosporium Mycosis 413
16.1 Pseudallescheria/Scedosporium Mycosis-at-a-Glance 413
16.2 Introduction/Disease Definition 414
16.3 Case Presentations 414
16.4 Diagnosis 416
16.5 Etiologic Agents 416
16.6 Geographic Distribution/Ecologic Niche 418
16.7 Epidemiology 419
16.7.1 Risk Groups/Factors 421
16.8 Transmission 421
16.9 Determinants of Pathogenicity 421
16.9.1 Host Factors 421
16.9.2 Microbial Factors 421
16.10 Clinical Forms 422
16.11 Veterinary Forms 423
16.12 Therapy 424
16.13 Laboratory Detection, Recovery, and Identification 426
Selected References for Pseudallescheria/Scedosporium Mycosis 428
Website Cited 429 Questions 429

17A. Mucormycosis 431
17A.1 Mucormycosis-at-a-Glance 433
17A.2 Introduction/Disease Definition 434
17A.3 Case Presentations 434
17A.4 Diagnosis 436
17A.5 Etiologic Agents 436
17A.6 Geographic Distribution/Ecologic Niche 437
17A.7 Epidemiology and Risk Groups/Factors 440
17A.8 Transmission 442
17A.9 Determinants of Pathogenicity 442
17A.9.1 Host Factors 442
19A.6 Risk Groups/Factors 497
19A.7 Transmission 497
19A.8 Determinants of Pathogenicity 497
19A.8.1 Microbial Factors 498
19A.9 Clinical Form 499
19A.10 Therapy 499

19B Cerebral Phaeohyphomycosis 499
19B.1 Introduction/Disease Definition 499
19B.2 Case Presentation 499
19B.3 Etiologic Agents 500
19B.4 Geographic Distribution/Ecologic Niche 500
19B.5 Epidemiology 501
19B.6 Risk Groups/Factors 501
19B.7 Transmission 502
19B.8 Determinants of Pathogenicity 502
19B.9 Clinical Form 502
19B.10 Therapy 502

19C Fungal Sinusitis 503
19C.1 Introduction/Disease Definition 503
19C.2 Clinical Forms 503
19C.3 Transmission 506
19C.4 Determinants of Pathogenicity 506
19C.5 Laboratory Detection, Recovery, and Identification 506
Selected References for Phaeohyphomycosis 509
Websites Cited 510
Questions 523

20. Eumycetoma (Madura Foot, Maduramycosis) 513
20.1 Eumycetoma at-a-Glance 513
20.2 Introduction/Disease Definition 513
20.3 Case Presentation 514
20.4 Diagnosis 514
20.5 Etiologic Agent(s) 514
20.6 Geographic Distribution/Ecologic Niche 515
20.7 Epidemiology 515
20.8 Risk Groups/Factors 516
20.9 Transmission 516
20.10 Determinants of Pathogenicity 516
20.10.1 Host Factors 516
20.10.2 Microbial Factors 516
20.11 Clinical Forms (Fahal, 2004) 517
20.12 Veterinary Forms 518
20.13 Therapy 518
20.14 Laboratory Detection, Recovery, and Identification 520
Selected References for Eumycetoma 522
Websites Cited 523
Questions 523

21. Dermatophytosis 527
21.1 Dermatophytosis-at-a-Glance 527
21.2 Introduction/Disease Definition 528
21.3 Case Presentations 529
21.4 Diagnosis 530
21.5 Etiologic Agents 530
21.6 Geographic Distribution/Ecologic Niche 534
21.7 Epidemiology 534
21.8 Risk Groups/Factors 537
21.9 Transmission 539
21.10 Determinants of Pathogenicity 540
21.10.1 Host Factors 540
21.10.2 Microbial Factors 541
21.11 Clinical Forms 542
21.12 Veterinary Forms 550
21.13 Therapy 552
21.14 Laboratory Detection, Recovery, and Identification 554
Selected References for Dermatophytosis 563
Website of Interest on the Subject of Dermatophytosis 565
Questions 565

22. Dermatomycoses 567
22A Major Nondermatophytic Fungi from Skin and Nails 567
22B Superficial Mycosis of the Hair Caused by a Nondermatophyte Mold: Black Piedra 569
22B.1 Introduction/Disease Definition 569
22B.2 Diagnosis 570
22B.3 Etiologic Agents 570
22B.4 Geographic Distribution/Ecologic Niche/Epidemiology 570
22B.5 Risk Groups/Transmission 570
22B.6 Determinants of Pathogenicity 570

Selected References for Eumycetoma 522
Websites Cited 523
Questions 523

Part Six Dermatophytosis and Dermatomycoses (Superficial Cutaneous Mycoses)